Locke Lord Assists Zydus Cadila in Acquisition of Stock Shares of Sentynl Therapeutics

Locke Lord assisted Zydus Cadila, an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies, in the acquisition of all of the shares of stock of Sentynl Therapeutics Inc., a San Diego-based commercial-stage specialty pharma company that specializes in marketing products in the pain management segment.  Locke Lord also provided assistance to Zydus in connection with the loan facility with Bank of Tokyo-Mitsubishi UFJ, which was used to fund the transaction.  Locke Lord lawyers Sean Fifield (Los Angeles), Joseph Farside (Providence), Buddy Sanders (Houston) and Juliane Dziobak (Chicago) worked on these transactions.
Posted January 24, 2017